Sofosbuvir + Peginterferon + Ribavirin in Genotypes 2 or 3

BOSON Trial

Foster GR, et al. 50th EASL. 2015. Abstract L05
**BOSON Trial: Features**

- **Design**: Randomized, multicenter, open-label trial using sofosbuvir and ribavirin with or without peginterferon for treatment naive or experienced patients with chronic HCV genotype 2 or 3

- **Setting**: International at 80 sites

- **Entry Criteria**
  - Chronic HCV Genotype 2, treatment experienced, with cirrhosis
  - Chronic HCV Genotype 3, +/- treatment experienced, +/- cirrhosis
  - Platelet ≥ 60,000 cells/mm³

- **End-Points**: SVR12; safety

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Treatment Arms

<table>
<thead>
<tr>
<th>Genotype 2</th>
<th>Prior treatment</th>
<th>Cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 3</td>
<td>+/- Prior Treatment</td>
<td>+/- Cirrhosis</td>
</tr>
</tbody>
</table>

**Sofosbuvir + RBV (n= 196)**

**Sofosbuvir + RBV (n= 199)**

**Sofosbuvir + PEG/RBV (n= 197)**

**Weeks:** 0, 12, 16, 24, 28, 36

**SVR12**

**Drug Dosing**

- Sofosbuvir 400 mg once daily
- Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg
- Peginterferon alfa-2a: 180 ug/week

**Source:** Foster GR, et al. 50th EASL. 2015. Abstract L05.
Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results

SVR12 by Regimen and Genotype

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3
BOSON: Results

Genotype 3: SVR12 by Regimen

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

BOSON: Results

Genotype 3: SVR12 by Regimen and Cirrhosis Status

Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

**BOSON: Results**

**Genotype 3: SVR12 by Regimen and Treatment History**

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.